Developer docs
API playgroundTry for free, no card

Search company profiles

Cellworks

Full company profile

uuid0000dv2

Namestring
Cellworks
Legal namestring
Cell Works Group, Inc.
Websiteurl
cellworks.life
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Cellworks is a life sciences technology company founded in 2005 and headquartered in South San Francisco, with an R&D center in Bangalore, India. The company has built a proprietary Computational Biology Model (CBM)—a mechanistic network of more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions—and applies it to predict patient-specific therapy response in oncology using multi-omics data (genomic, proteomic, transcriptomic, epigenomic). Its clinical products include the Singula™ Therapy Response Index (TRI) reports, the ΔTRI classifier for metastatic NSCLC chemo-immunotherapy benefit prediction, a Drug-Drug Interaction (DDI) risk assessment tool, and liquid biopsy analysis, all delivered through a physician portal and supported by a CLIA-certified computational laboratory in Franklin, Tennessee.

The company operates two primary revenue motions: a clinical decision support service delivering personalized therapy predictions to oncologists and health systems, and a pharma services business offering virtual clinical trials, target identification, lead validation, and drug repurposing/rescue to biopharmaceutical clients. GTM is enterprise field sales targeting pharma R&D teams, medical directors at health systems, and practicing oncologists, supplemented by a strong scientific conference and peer-reviewed publication presence at ASCO, ASH, AACR, and WCLC. Backed by Artiman Ventures, Sequoia Capital, UnitedHealth Group, Bering Capital, and Agilent Ventures, Cellworks has raised approximately $33M in disclosed funding across rounds (2009, 2012, 2020), with the most recent $15.5M round in June 2020. Board advisors include former ASCO CEO Dr. Allen Lichter and former UnitedHealth Group Cancer Director Dr. Lee Newcomer.

Short descriptiontext

Cellworks is a life sciences technology company using mechanistic AI computational biosimulation to predict personalized cancer therapy responses for oncologists, pharmaceutical companies, and payers via its CLIA-certified lab and Singula TRI reports.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational biosimulation, personalized therapy prediction, precision medicine oncology, multi-omics biosimulation, drug response prediction
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code4 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Prepackaged Software7372
Product category
Computational Precision Medicine / Oncology Decision Support
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Decision Support Services
TypeSubscription Recurring
Description

Cellworks provides personalized therapy prediction services to physicians and healthcare systems through its CLIA-certified computational lab, generating revenue from test ordering and analysis services.

cellworks.life
2Pharma Drug Development Services
TypeProfessional Services
Description

Pharma services include virtual clinical trials, improved target identification, lead validation, and ability to repurpose and rescue drugs using the biosimulation platform.

cellworks.life
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Singula
Description

Personalized therapy response prediction platform that uses multi-omics biosimulation to predict drug efficacy for individual cancer patients.

cellworks.life
+4 more records
Core offering1 text field

Cellworks provides a computational biosimulation platform that uses mechanistic AI and multi-omics modeling to predict patient-specific cancer therapy response. Its core engine, the Computational Biology Model (CBM), biosimulates how FDA-approved drugs and combinations affect disease pathways using genomic, proteomic, transcriptomic, and epigenomic data. Outputs are delivered as Singula TRI reports through a CLIA-certified lab and physician portal for clinical decision support, and as pharma services for drug development, virtual trials, and drug repurposing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% accuracy in predicting therapy response for AML and MDS patients
+4 more records
Product overview1 text field

Cellworks offers a unified biosimulation platform with multiple integrated products and services. The core is the Cellworks Biosimulation Platform powered by the Computational Biology Model (CBM), a mechanistic network of 6,000+ genes used to predict therapy response. This platform is accessed through physician-facing Singula™ TRI reports and a physician portal. The myCare™ clinical trial suite provides clinical study services that generate personalized therapy predictions. Additional products include the ΔTRI classifier for NSCLC treatment selection, a DDI risk assessment tool for oncology, and liquid biopsy analysis capabilities. Services span clinical decision support for physicians, payer solutions for insurance providers, and pharma services for drug development. The company also operates a CLIA-certified computational lab in Franklin, Tennessee.

Product and service13 records
1Cellworks Biosimulation Platform
CategoryCore platform / biosimulation technology
Description

A computational biology platform that applies mechanistic AI to perform computational biosimulation of protein-protein interactions, enabling in silico modeling of tumor behavior from next-generation sequencing (NGS) data. Used to predict patient-specific therapy response in oncology and other complex diseases.

2Computational Biology Model (CBM)
CategoryCore platform / computational biology model
Description

A proprietary mechanistic network model encompassing more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions. The CBM biosimulates how specific compounds or combinations affect disease pathways to produce therapy response predictions.

3Singula TRI (Therapy Response Index)
CategoryClinical decision support / personalized therapy prediction
Description

A therapy response prediction tool that delivers personalized overall survival (OS) and progression-free survival (PFS) predictions across multiple cancer types including NSCLC, GBM, LGG, AML, MDS, and pancreatic cancer. Predicts which drug therapies will produce response in a specific patient based on molecular aberrations.

4myCare Clinical Trials
CategoryClinical trial services / clinical evidence generation
Description

A suite of clinical studies (myCare-009, myCare-021, myCare-040) that apply Cellworks biosimulation to interpret NGS data and deliver actionable therapy recommendations. Includes myCare-101, a prospective clinical trial for newly diagnosed, relapsed, or refractory cancer patients.

5Singula Reports
CategoryClinical decision support / personalized therapy prediction
Description

Reports delivered to oncologists and patients that predict which FDA-approved cancer therapies will produce response for a specific patient based on molecular aberrations, overcoming the 'one-mutation one-drug' limitation of standard NGS analysis.

6Singula Ventura
CategoryClinical decision support / personalized therapy prediction
Description

A variant of the Singula therapy response prediction report offered through the myCare clinical trial program for cancer patients.

7Physician Portal
CategoryClinical decision support / ordering and delivery platform
Description

A web portal enabling qualified healthcare professionals to order tests, access patient information, laboratory test results, and relevant documentation to support personalized therapy decision-making.

8ΔTRI Classifier
CategoryClinical decision support / NSCLC classifier
Description

A novel classifier developed from the myCare-040 clinical study that uses tumor-specific genomic data to predict which metastatic NSCLC patients are likely to benefit from chemo-immunotherapy versus immunotherapy alone. A ΔTRI score ≥16 identifies patients likely to gain 8.3 months median OS improvement.

9DDI Risk Assessment Tool
CategoryClinical decision support / drug-drug interaction prediction
Description

A mechanistically-based drug-drug interaction risk assessment tool that integrates FDA drug label data with gene-level mechanistic insights to identify and classify clinically relevant DDIs in cancer combination therapies. Achieved 100% accuracy against curated datasets.

10Liquid Biopsy Analysis
CategoryClinical decision support / liquid biopsy genomic analysis
Description

Liquid biopsy genomic profiling as an alternative to solid tissue profiling for predicting benefit from chemo-immunotherapy in advanced NSCLC. Cellworks' predictive scores derived from liquid biopsy samples show strong alignment with solid tissue scores (R² = 0.61).

11CLIA-Certified Computational Lab
CategoryClinical laboratory services
Description

A CLIA-certified computational laboratory in Franklin, Tennessee that performs genomic biosimulation testing to advance personalized therapy decision support services.

12Payer Solutions
CategoryPayer engagement services
Description

Services for payers providing effective intervention recommendations for better patient outcomes, prolonging lives and reducing costs through precision medicine approaches.

13Pharma Services
CategoryPharma drug development services
Description

Precision drug development services including virtual clinical trials, improved target identification, lead validation, and drug repurposing/rescue programs for biopharma companies.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cellworks collaborates with global partners on clinical research, with findings featured in 125+ peer-reviewed presentations and publications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Charu Aggarwal, MD from Perelman School of Medicine serves as Co-Principal Investigator on myCare-040 study for NSCLC research.

3University of Colorado School of Medicine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tejas Patil, MD serves as Co-Principal Investigator on NSCLC clinical studies.

cellworks.life
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Guido Marcucci and Dr. Anthony Stein served as Primary Investigators for myCare-009-01 and myCare-009-02 AML and MDS clinical studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine (Roche subsidiary) is a leading molecular profiling company that provides genomic analysis and clinical decision support for oncology patients. It competes directly with Cellworks' Singula clinical decision support offering while operating at much larger scale with established hospital integrations.

2Tempus Labs
TypeDirect peer
Description

Tempus is a precision medicine company combining multi-omics data, AI, and clinical decision support for oncology. Both companies leverage NGS + AI to predict therapy response and offer pharma R&D services, making Tempus the closest direct competitor in both clinical and pharma verticals.

TypeEmerging player
Description

Inspirata provides a digital pathology and cancer diagnostics platform leveraging AI for oncology decision support and clinical trial workflows. It overlaps with Cellworks' clinical decision support and pharma trial services verticals.

TypeDirect peer
Description

MolecularHealth offers a treatment decision support platform that matches patient molecular data with drug response evidence. Its functional overlap with Singula's therapy response prediction positions it as a direct niche competitor in molecular tumor board informatics.

TypeDirect peer
Description

Caris offers molecular profiling (MI Profile) and AI-driven therapy decision support across multiple cancer types. It overlaps directly with Cellworks on multi-omics based therapy response prediction and serves a similar oncologist customer base.

TypeBroad incumbent
Description

Guardant Health is a leader in liquid biopsy and genomic profiling for oncology. Its Guardant360 CDx test competes with Cellworks' solid tissue and liquid biopsy Singula workflow, and it has deeper payer reimbursement infrastructure.

TypeEmerging player
Description

Exscientia is an AI-driven drug discovery company that uses precision medicine platforms for both pharma partnerships and patient stratification. It overlaps with Cellworks' pharma services (target ID, lead optimization, virtual trials) and is developing precision oncology capabilities.

TypeEmerging player
Description

PathAI applies AI to pathology and precision oncology, including diagnostic decision support and pharma biomarker discovery. It serves a similar customer base (oncologists, pharma R&D) and competes for AI-driven oncology analytics budgets.

TypeEmerging player
Description

GNS Healthcare applies causal AI and biosimulation to drug discovery and clinical development for pharma partners. Its mechanism-based AI modeling approach is highly analogous to Cellworks' CBM and competes for pharma services budgets.

TypeEmerging player
Description

Owkin applies AI to patient data for drug discovery and clinical research across pharma and provider markets. It overlaps with Cellworks' pharma services vertical (target ID, clinical trial optimization) and is building AI-driven oncology decision support.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellworks

Computational Precision Medicine / Oncology Decision Supportcellworks.life

Cellworks is a life sciences technology company using mechanistic AI computational biosimulation to predict personalized cancer therapy responses for oncologists, pharmaceutical companies, and payers via its CLIA-certified lab and Singula TRI reports.

What Cellworks does

Cellworks is a life sciences technology company founded in 2005 and headquartered in South San Francisco, with an R&D center in Bangalore, India. The company has built a proprietary Computational Biology Model (CBM)—a mechanistic network of more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions—and applies it to predict patient-specific therapy response in oncology using multi-omics data (genomic, proteomic, transcriptomic, epigenomic). Its clinical products include the Singula™ Therapy Response Index (TRI) reports, the ΔTRI classifier for metastatic NSCLC chemo-immunotherapy benefit prediction, a Drug-Drug Interaction (DDI) risk assessment tool, and liquid biopsy analysis, all delivered through a physician portal and supported by a CLIA-certified computational laboratory in Franklin, Tennessee.

The company operates two primary revenue motions: a clinical decision support service delivering personalized therapy predictions to oncologists and health systems, and a pharma services business offering virtual clinical trials, target identification, lead validation, and drug repurposing/rescue to biopharmaceutical clients. GTM is enterprise field sales targeting pharma R&D teams, medical directors at health systems, and practicing oncologists, supplemented by a strong scientific conference and peer-reviewed publication presence at ASCO, ASH, AACR, and WCLC. Backed by Artiman Ventures, Sequoia Capital, UnitedHealth Group, Bering Capital, and Agilent Ventures, Cellworks has raised approximately $33M in disclosed funding across rounds (2009, 2012, 2020), with the most recent $15.5M round in June 2020. Board advisors include former ASCO CEO Dr. Allen Lichter and former UnitedHealth Group Cancer Director Dr. Lee Newcomer.

Cellworks firmographics

Firmographics
Name
Cellworks
Legal name
Cell Works Group, Inc.
Website
https://cellworks.life
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Cellworks is a life sciences technology company using mechanistic AI computational biosimulation to predict personalized cancer therapy responses for oncologists, pharmaceutical companies, and payers via its CLIA-certified lab and Singula TRI reports.
Ownership category
akta.pro rank

Cellworks industry classification

Industry
Product category
Computational Precision Medicine / Oncology Decision Support
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational biosimulation
  • Personalized therapy prediction
  • Precision medicine oncology
  • Multi-omics biosimulation
  • Drug response prediction

Where Cellworks is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Cellworks business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Clinical Decision Support Services: Cellworks provides personalized therapy prediction services to physicians and healthcare systems through its CLIA-certified computational lab, generating revenue from test ordering and analysis services.
  2. Pharma Drug Development Services: Pharma services include virtual clinical trials, improved target identification, lead validation, and ability to repurpose and rescue drugs using the biosimulation platform.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Cellworks product offering

Product offering

Core offering

Cellworks provides a computational biosimulation platform that uses mechanistic AI and multi-omics modeling to predict patient-specific cancer therapy response. Its core engine, the Computational Biology Model (CBM), biosimulates how FDA-approved drugs and combinations affect disease pathways using genomic, proteomic, transcriptomic, and epigenomic data. Outputs are delivered as Singula TRI reports through a CLIA-certified lab and physician portal for clinical decision support, and as pharma services for drug development, virtual trials, and drug repurposing.

Product overview

Cellworks offers a unified biosimulation platform with multiple integrated products and services. The core is the Cellworks Biosimulation Platform powered by the Computational Biology Model (CBM), a mechanistic network of 6,000+ genes used to predict therapy response. This platform is accessed through physician-facing Singula™ TRI reports and a physician portal. The myCare™ clinical trial suite provides clinical study services that generate personalized therapy predictions. Additional products include the ΔTRI classifier for NSCLC treatment selection, a DDI risk assessment tool for oncology, and liquid biopsy analysis capabilities. Services span clinical decision support for physicians, payer solutions for insurance providers, and pharma services for drug development. The company also operates a CLIA-certified computational lab in Franklin, Tennessee.

Differentiator

Problem solved

Functional benefit

Brands

  • Singula: Personalized therapy response prediction platform that uses multi-omics biosimulation to predict drug efficacy for individual cancer patients.
  • myCare
  • Singula TRI (Therapy Response Index)
  • Singula Lung
  • Ventura

Products and services

  • Cellworks Biosimulation Platform A computational biology platform that applies mechanistic AI to perform computational biosimulation of protein-protein interactions, enabling in silico modeling of tumor behavior from next-generation sequencing (NGS) data. Used to predict patient-specific therapy response in oncology and other complex diseases.
  • Computational Biology Model (CBM) A proprietary mechanistic network model encompassing more than 6,000 human genes, 30,000 molecular species, and 600,000 molecular interactions. The CBM biosimulates how specific compounds or combinations affect disease pathways to produce therapy response predictions.
  • Singula TRI (Therapy Response Index) A therapy response prediction tool that delivers personalized overall survival (OS) and progression-free survival (PFS) predictions across multiple cancer types including NSCLC, GBM, LGG, AML, MDS, and pancreatic cancer. Predicts which drug therapies will produce response in a specific patient based on molecular aberrations.
  • myCare Clinical Trials A suite of clinical studies (myCare-009, myCare-021, myCare-040) that apply Cellworks biosimulation to interpret NGS data and deliver actionable therapy recommendations. Includes myCare-101, a prospective clinical trial for newly diagnosed, relapsed, or refractory cancer patients.
  • Singula Reports Reports delivered to oncologists and patients that predict which FDA-approved cancer therapies will produce response for a specific patient based on molecular aberrations, overcoming the 'one-mutation one-drug' limitation of standard NGS analysis.
  • Singula Ventura A variant of the Singula therapy response prediction report offered through the myCare clinical trial program for cancer patients.
  • Physician Portal A web portal enabling qualified healthcare professionals to order tests, access patient information, laboratory test results, and relevant documentation to support personalized therapy decision-making.
  • ΔTRI Classifier A novel classifier developed from the myCare-040 clinical study that uses tumor-specific genomic data to predict which metastatic NSCLC patients are likely to benefit from chemo-immunotherapy versus immunotherapy alone. A ΔTRI score ≥16 identifies patients likely to gain 8.3 months median OS improvement.
  • DDI Risk Assessment Tool A mechanistically-based drug-drug interaction risk assessment tool that integrates FDA drug label data with gene-level mechanistic insights to identify and classify clinically relevant DDIs in cancer combination therapies. Achieved 100% accuracy against curated datasets.
  • Liquid Biopsy Analysis Liquid biopsy genomic profiling as an alternative to solid tissue profiling for predicting benefit from chemo-immunotherapy in advanced NSCLC. Cellworks' predictive scores derived from liquid biopsy samples show strong alignment with solid tissue scores (R² = 0.61).
  • CLIA-Certified Computational Lab A CLIA-certified computational laboratory in Franklin, Tennessee that performs genomic biosimulation testing to advance personalized therapy decision support services.
  • Payer Solutions Services for payers providing effective intervention recommendations for better patient outcomes, prolonging lives and reducing costs through precision medicine approaches.
  • Pharma Services Precision drug development services including virtual clinical trials, improved target identification, lead validation, and drug repurposing/rescue programs for biopharma companies.

Quantifiable outcome

  • 90% accuracy in predicting therapy response for AML and MDS patients
  • +4 more outcomes

Companies that use Cellworks

Customer profile

Segments4 records

Ideal customer profiles3 records

Cellworks technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Cellworks partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Global Research CollaboratorscoreStrategic or Co-development PartnerCellworks collaborates with global partners on clinical research, with findings featured in 125+ peer-reviewed presentations and publications.
  • University of PennsylvaniacoreStrategic or Co-development PartnerCharu Aggarwal, MD from Perelman School of Medicine serves as Co-Principal Investigator on myCare-040 study for NSCLC research.
  • University of Colorado School of MedicinecoreStrategic or Co-development PartnerTejas Patil, MD serves as Co-Principal Investigator on NSCLC clinical studies.
  • City of HopecoreStrategic or Co-development PartnerDr. Guido Marcucci and Dr. Anthony Stein served as Primary Investigators for myCare-009-01 and myCare-009-02 AML and MDS clinical studies.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Cellworks competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine: Foundation Medicine (Roche subsidiary) is a leading molecular profiling company that provides genomic analysis and clinical decision support for oncology patients. It competes directly with Cellworks' Singula clinical decision support offering while operating at much larger scale with established hospital integrations.
  • Guardant Health: Guardant Health is a leader in liquid biopsy and genomic profiling for oncology. Its Guardant360 CDx test competes with Cellworks' solid tissue and liquid biopsy Singula workflow, and it has deeper payer reimbursement infrastructure.

Direct peers

  • Tempus Labs: Tempus is a precision medicine company combining multi-omics data, AI, and clinical decision support for oncology. Both companies leverage NGS + AI to predict therapy response and offer pharma R&D services, making Tempus the closest direct competitor in both clinical and pharma verticals.
  • MolecularHealth: MolecularHealth offers a treatment decision support platform that matches patient molecular data with drug response evidence. Its functional overlap with Singula's therapy response prediction positions it as a direct niche competitor in molecular tumor board informatics.
  • Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven therapy decision support across multiple cancer types. It overlaps directly with Cellworks on multi-omics based therapy response prediction and serves a similar oncologist customer base.

Emerging players

  • Inspirata: Inspirata provides a digital pathology and cancer diagnostics platform leveraging AI for oncology decision support and clinical trial workflows. It overlaps with Cellworks' clinical decision support and pharma trial services verticals.
  • Exscientia: Exscientia is an AI-driven drug discovery company that uses precision medicine platforms for both pharma partnerships and patient stratification. It overlaps with Cellworks' pharma services (target ID, lead optimization, virtual trials) and is developing precision oncology capabilities.
  • PathAI: PathAI applies AI to pathology and precision oncology, including diagnostic decision support and pharma biomarker discovery. It serves a similar customer base (oncologists, pharma R&D) and competes for AI-driven oncology analytics budgets.
  • GNS Healthcare: GNS Healthcare applies causal AI and biosimulation to drug discovery and clinical development for pharma partners. Its mechanism-based AI modeling approach is highly analogous to Cellworks' CBM and competes for pharma services budgets.
  • Owkin: Owkin applies AI to patient data for drug discovery and clinical research across pharma and provider markets. It overlaps with Cellworks' pharma services vertical (target ID, clinical trial optimization) and is building AI-driven oncology decision support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Cellworks social profiles

Digital presence

Cellworks compliance and trust

Trust signal

Compliance4 records

Cellworks financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellworks leadership team

Management profile

Number of profiles

Profiles8 records

Cellworks funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellworks M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellworks

What does Cellworks do?

Cellworks provides a computational biosimulation platform that uses mechanistic AI and multi-omics modeling to predict patient-specific cancer therapy response. Its core engine, the Computational Biology Model (CBM), biosimulates how FDA-approved drugs and combinations affect disease pathways using genomic, proteomic, transcriptomic, and epigenomic data. Outputs are delivered as Singula TRI reports through a CLIA-certified lab and physician portal for clinical decision support, and as pharma services for drug development, virtual trials, and drug repurposing.

Is Cellworks a public or private company?

Cellworks is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellworks founded?

Cellworks was founded in 2005. It employs 101 to 250 people.

Where is Cellworks based?

Cellworks is headquartered in South San Francisco, United States, in the North America region.

How does Cellworks make money?

Two revenue lines are on record. Clinical Decision Support Services are the primary driver. The others are pharma Drug Development Services.

Who are Cellworks's main competitors?

Broad incumbents on record are Foundation Medicine and Guardant Health. Direct peers are Tempus Labs, MolecularHealth and Caris Life Sciences. Emerging players are Inspirata, Exscientia, PathAI, GNS Healthcare and Owkin.

Does Cellworks have an API?

No public API is recorded for Cellworks.

What industry is Cellworks in?

Cellworks's product category is Computational Precision Medicine / Oncology Decision Support. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCellworks Expands Evidence for Predicting Chemo-Immunotherapy Benefit in NSCLC with New Early-Stage Disease StudyCellworks presented a study at AACR 2026 showing its AI platform predicts chemo-immunotherapy benefit in early-stage NSCLC. The ∆TRI algorithm identified a 19.4-month median OS improvement in the High Benefit group, while the No Benefit group saw no advantage. The findings suggest the same biology applies across disease stages.EIN PresswireCellworks Presents Novel Mechanistic Approach to Predicting Drug–Drug Interaction Risk in Oncology at AACR 2026Cellworks presented a drug–drug interaction risk assessment tool at AACR 2026 that integrates mechanistic biology, gene interactions, and clinical evidence. The tool achieved 100% accuracy on a curated dataset, identifying 6.8% of 544 predicted pairs as DDI-positive, with nearly 19% having documented clinical trial failures.EIN PresswireCellworks Study Supports Liquid Biopsy for Predicting Chemo-Immunotherapy Benefit in Advanced NSCLCA Cellworks study presented at AACR 2026 found that liquid biopsy genomic profiling strongly aligns with solid tissue profiling for predicting chemo-immunotherapy benefit in advanced NSCLC. The median difference in predicted benefit was 2.39, roughly a 2% difference, and discordance was driven 81% of the time by novel liquid-detected mutations.Cosmetics BusinessISP and Cellworks Group collaborate on biofunctional developmentISP Personal Care announced an alliance with Cellworks Group to accelerate discovery of biofunctional skin care ingredients. ISP used Cellworks' Virtual Skin platform to model efficacy of two pigmentation ingredients, predicting effects on different skin types. The collaboration aims to precede work on anti-ageing compounds and ingredient synergies.Business Wire BlogCellworks Unveils a Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLCCellworks Group Inc. announced results from the myCare-040 clinical study demonstrating that its computational biology model can predict which metastatic NSCLC patients are likely to benefit from chemo-immunotherapy versus immunotherapy alone, with 22% of the validation cohort (High Benefit) achieving a median overall survival increase of 8.3 months with chemo-immunotherapy while 78% showed no survival advantage from adding chemotherapy. The novel ΔTRI classifier uses tumor-specific genomic data from next-generation sequencing and was validated in an independent cohort of 328 patients, with predictions proving independent of PD-L1 status. Findings were presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain.GlobeNewswireFormer UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of DirectorsCellworks Group announced that Dr. Lee Newcomer, former cancer director for UnitedHealth Group, has been elected to its board of directors. He joins a board that includes Dr. Allen Lichter, Dr. Bill Rutter, and Dr. David Lawrence. The company's biosimulation platform aims to improve personalized cancer treatments.GlobeNewswireOnconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual MeetingOnconova and Cellworks presented a retrospective analysis of the ONTIME Phase 3 trial at ASH 2016, identifying a predictive signature for rigosertib response in higher-risk MDS. The signature correlated with trisomy 8 and 21, validating enrollment criteria for the ongoing INSPIRE trial.